Skip to main content

Table 1 Distribution of TKI-associated VAEs and other relevant toxicities, among the various TKIs in CML

From: Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

 

Imatinib

Nilotinib

Dasatinib

Bosutinib

Ponatinib

PAOD

 

++

 

+/−

++

IHD/CVA

 

+

  

+

VTE

    

+

Pulmonary hypertension

  

+

  

Platelet dysfunction

  

+

 

+

Hypertension

   

+

++

Hyperglycemia

a

+

   

Dyslipidemia

a

+

   
  1. CVA cerebrovascular accident, IHD ischemic heart disease, PAOD peripheral arterial occlusive disease, TKI tyrosine kinase inhibitor, VAE vascular adverse event, VTE venous thrombo-embolism
  2. aImatinib has been shown to have positive effects on glucose blood levels, as well as lipid profile (See text for details)